ImmunityBio (IBRX) stock

Cancer immunotherapies , market cap $8.5B

Cancer immunotherapies

Worth $8.5B

$6.75

-5.13%

As of Tuesday's close · Live for Pro members at the open

Why is IBRX down?

Down 5.1% today, more than its biotech peers' 1.4%; no story names it yet.

Fell 25% since Nov 4

Down 25% from Nov 4 to Nov 10.

ImmunityBio fell 25% from Nov 4 to Nov 10. 17 points of it came on Nov 9, the day of its results.

Sources: Price history, Nov 10, 2026; SEC filing, Nov 9, 2026

Tell me next time IBRX moves

Free account, no card. An optional alert when IBRX moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →3 more reasons why IBRX fell 25% since Nov 4, from its filings, with how the business stands, the timeline, and its peers, for Pro members.

Why IBRX still beats the market over a year

Up 229% over the year to Nov 9 while the S&P 500 rose 12%; down 24% since Nov 4.

5 reasons, from its filings, with the timeline, for Pro members.

Quality Score

Below Average

In its industry

#137of 281

Biotech

Checks firing

1of 14

Transition

From 52-week high

-45.7%

under its best in a year

IBRX's Quality Score fell 2 points on Tue, Nov 10, to 0. Trading went back to normal after a busy day (2 chart checks stopped).

Follow IBRX's trial news. Pro members can get an alert when ImmunityBio files news, and see its trials, share raises, and its CEO's filings.

Get an alert when IBRX files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“…supplemental Biologics License Application (sBLA) remains on track for submission to the FDA by year-end 2026…”Filing with regulators · SEC filing · Nov 9

Cash$334M, about 4 quarters at the last year's spendingOn Sep 30

Key facts on IBRX

Key facts on IBRX
Holding it back	Moves 11.5% a day with no profit behind it
Latest filing	8-K, Nov 9 Reported its quarterly results

1 more reason behind IBRX's 0, free with an account →6 more reasons behind IBRX's 0, for Pro members.

IBRX in the news

TodayNo story names it yet.

What's next

Mon Nov 16: Jefferies 17th Annual London Global…Investor conference · date confirmed.

Expected to report Mon Feb 22, before the open

After its last 4 reports it closed -3.7% on average, higher 1 of 4 times.

3 more dates ahead: conferences, for Pro members.

Cash$334M, about 4 quarters at the last year's spendingOn Sep 30

IBRX catalysts

Coming up

6 more coming up and 10 past catalysts since 2020, with sizes and sources, for Pro members.

What's next for IBRX, and how long its cash lasts

Next step the company has named

End of 2026“A supplemental Biologics License Application (sBLA) remains on track for submission to the FDA by year-end 2026, potentially expanding ANKTIVA’s indication to include patients with NMIBC…”Filing with regulators · SEC filing · Nov 9

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway: Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor TherapyPhase 3 · Recruiting · 507 people · main data estimated Sep 2028 · NCT06745908

20 more trials, 1 with data due this year, 2 more milestones and 41 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 4 quarters

$334M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Apr 17, 2024)
At-the-market share sales program (S-3ASR, filed Apr 17, 2024)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

Director Barry J. Simon sold 25,000 shares on Oct 5, under a planned sale. 11 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Richard Adcock buys or sells

For Pro members: every trade, and Richard Adcock’s 21 filings and quotes.

Get an alert when IBRX files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why IBRX scores 0

Below Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

Well below its recent run. IBRX scores 0 today, against a median of 5 over its last 20 recorded sessions.

+2Run-up 217% over 12 months
−2Volatility moves 11.5% a day on a $1.1B loss over four quarters, with no positive free cash flowA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

Chart checks adds
Long-term trend adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
News subtracts

No effect today: Size and Persistence.

What every line is worth, and the reason behind it, on IBRX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How IBRX ranks in Biotech

IBRX is #137 of 281 by Quality Score.

How IBRX ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	HURATuHURA Biosciences		Open for its score
	IAMIambic Therapeutics		Open for its score
	ICLRIcon		Open for its score
	IDYAIDEAYA Biosciences		Open for its score
137	IBRXImmunityBio	1/14	0

Share count against a year before: IBRX +12%, HALO -2.9%, IOVA +25%, CGON +16%.

When does IBRX report earnings, and what happens after?

Expected to report Mon Feb 22, before the open (in 104 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What IBRX reported on Nov 9, 2026

The quarter

Sales of $48.8M, 52% more than a year ago; a loss of $0.18 a share, from $0.07.

“Product revenue, net increased $17.0 million during the three months ended September 30, 2026, as compared to the three months ended September 30, 2025, due to an increase in sales of ANKTIVA.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Productup 53%	$48.7M99%	$50.7M99%	$31.8M99%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 9)

3 more lines, for Pro members.

The outlook

No outlook figures read from this release.

In the company's words

“The increase in net loss was mainly driven by changes in the fair value of a related-party convertible note, and warrant and derivative liabilities due to an increase in our common stock price during the quarter, higher interest expense related to the revenue interest liability, and higher R&D and SG&A expenses described above, which were partially offset by higher product revenue.”

From its results filing (SEC filing · Nov 9)

1 more sentence, for Pro members.

The numbers

Market value: $8.5B; today
Sales: $183M; up 121% on the year
Free cash flow: -$297M; last 12 months

Its share count grew 20% a year over 5 years.

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on IBRX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-7.4%-2.8%-17.7%

May 7Aug 4Nov 9

Reported	When	Gap	Reaction	5 days
Nov 9, 2026Before open	Before open	-16.4%	-17.7%	not yet
Aug 4, 2026Before open	Before open	-5.5%	-2.8%	+4.8%
May 7, 2026Before open	Before open	-6.7%	-7.4%	-2.7%

IBRX closed higher after 1 of its last 4 reports.

All 4 reports, and IBRX's Quality Score going into each

IBRX sales and profit by year

Sales and profit by year

Sales grew in five of the last seven years, to $113M in 2025. It lost money in each of the eight years.

IBRX has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on IBRX, and all 14 on every stock.Get in free →

IBRX RSI today: 36.6, below its 50-day and 200-day averages

Not scored

RSI 36.6, MACD below signal, below both averages. Not scored.13 readings

The deep dive on IBRX

What it does and how it makes money5 findingsAn operating loss of $256M in fiscal 2025, on $113M of sales.Annual report, filed Feb 23, 2026"In June 2024, we submitted applications to the USPTO for the extension of the patent term of several U.S. patents directed to compositions of matter of N-803, methods of use of N-803 and methods of manufacture of N-803." (10-K for fiscal 2025)SEC filing · Feb 23, 2026
Where it stands5 findingsFor Pro members5 findings on where IBRX stands: its cash, debt, and share count, for Pro members
What changed in its filings4 findings"The company filed its response on November 19, 2025, and an arbitrator was appointed on January 16, 2026." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 9, 2026New in its "Risk Factors" this year: "The Consolidated Appropriations Act of 2026, signed into law in February 2026, codified this longstanding FDA interpretation of the Orphan Drug Act, allowing the FDA to approve multiple versions of the same orphan drug for different subindications and subpopulations." (10-K for fiscal 2025)SEC filing · Feb 23, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades IBRX, for Pro members
Against its closest peers4 peersShare count against a year before: IBRX +12%, HALO -2.9%, IOVA +25%, CGON +16%.

12 more findings on IBRX, each with its source, for Pro members.

IBRX share count over time

12% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of IBRX outstanding, as filed
Shares outstanding	As of
1.06B	Nov 3, 2026
1.06B	Jul 31, 2026
1.05B	May 5, 2026
1.03B	Feb 19, 2026

Offerings, shelves, and splits of IBRX, from its filings
From its filings	Filed
Raised $80M in a sale of shares	Jul 28, 2025
Raised $75M in a sale of shares	Apr 8, 2025
Raised $100M in a sale of shares, about 1% of its market value	Dec 12, 2024
Registered shares for a later sale (S-3ASR)	Apr 17, 2024

IBRX insider trades

IBRX trades by Congress and the executive branch

2 trades disclosed in the last six months. The newest:

BuyLisa McClain$1K to $15KHousetraded Sep 30, disclosed Oct 12(12 days later)

BuyLisa McClainHouse$1K to $15Ktraded Sep 30, disclosed Oct 12(12 days later)

All 2 trades on IBRX disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

IBRX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Richard AdcockCEO & President · no trades on file
David C. SachsChief Financial Officer · no trades on file
Patrick Soon-ShiongOfficer · no trades on file
Regan J. LauerChief Accounting Officer · no trades on file
Barry J. SimonDirector · 7 trades
Christobel SeleckyDirector · 6 trades
Cheryl CohenDirector · 2 trades

See insider trades by person

Which ETFs hold IBRX?

In ETFs: IBRX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About ImmunityBio

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

691 employeesSan Diego, CAimmunitybio.com

What ImmunityBio says it competes with

“The biotechnology and pharmaceutical industries are intensely competitive.”

From its annual report, SEC filing · Feb 23, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on IBRX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn IBRX's score around: 8 things
9 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 12Lisa McClain bought IBRX$1K to $15K, disclosed Oct 12

Alerts are optional.

See IBRX's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: IBRX's Quality Score is 0 (Below Average), #137 of 281 in Biotech.

What does IBRX's Quality Score say?

IBRX scores 0 today, which Breakaway calls Below Average. It is #137 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 25% from Nov 4 to Nov 10. Cash lasts about 4 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is IBRX's Quality Score?

IBRX scores 0 today, which Breakaway calls Below Average (0 to 5). That is #137 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IBRX's 0.

When does IBRX report earnings?

Expected to report Mon Feb 22, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. IBRX closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.